Tofacitinib withdrawal and retreatment in moderate‐to‐severe chronic plaque psoriasis: a randomized controlled trial. (1st May 2015)

• Record Type: Journal Article
• Authors: Bissonnette, R.; Iversen, L.; Sofen, H.; Griffiths, C.E.M.; Foley, P.; Romiti, R.; Bachinsky, M.; Rottinghaus, S.T.; Tan, H.; Proulx, J.; Valdez, H.; Gupta, P.; Mallbris, L.; Wolk, R.
• Is Part Of: British journal of dermatology. Volume 172:Number 5(2015:May)
• Page Start: 1395
• Page End: 1406
• Publication Date: 2015-05-01
• Subjects: Dermatology -- Periodicals; Skin -- Diseases -- Periodicals; 616.5
• DOI: 10.1111/bjd.13551
• Languages: English
• ISSNs: 0007-0963

Abstract

Summary: Background: Tofacitinib is an oral Janus kinase inhibitor being investigated for the treatment of moderate‐to‐severe plaque psoriasis. Objectives: To compare outcomes following tofacitinib withdrawal with outcomes of continuation. Methods: In this phase 3 study (NCT01186744), patients received tofacitinib 5 mg ( n = 331) or 10 mg ( n = 335) twice daily for 24 weeks. The patients who achieved both ≥ 75% reduction in Psoriasis Area and Severity Index (PASI 75) score from baseline and Physician's Global Assessment (PGA) of 'clear' or 'almost clear' (PGA response) received a placebo (withdrawal) or the previous dose. At relapse (> 50% reduction in the PASI improvement during initial treatment) or week 40, the patients received the initial dose. Results: Initial treatment: 33·5% and 55·2% achieved both PASI 75 and PGA responses with tofacitinib 5 and 10 mg twice daily, respectively, making them eligible for the treatment‐withdrawal period. Withdrawal: 56·2%, 62·3%, 23·3% and 26·1% maintained PASI 75 responses with tofacitinib 5, 10 mg, placebo (5 mg) and placebo (10 mg) twice daily, respectively; 49·9%, 63·9%, 22·9% and 18·0% maintained PGA responses; and 92·3%, 93·0%, 32·8% and 42·9% did not relapse. Elevations in low‐density lipoprotein–cholesterol levels following initial treatment (mean increase: 8·71 mg dL −1 with 5 mg twice daily, 10·26 mg dL −1 with 10 mg twice daily) were reversed upon withdrawal. Retreatment: 36·8% and 61·0% of patients who relapsed achieved PASI 75 responses with tofacitinib 5 or 10 mg after 16 weeks; 44·8% and 57·1% regained PGA responses. Conclusions: Patients who received continuous treatment maintained a response more effectively when compared with placebo recipients. Safety profiles were comparable in both the continuous treatment group and retreatment group. Of those patients who relapsed, up to 60% recaptured a response with tofacitinib.